T1	Participants 65 107	patients receiving intravenous antibiotics
T2	Participants 404 465	patient group receiving prolonged courses of i.v. antibiotics
T3	Participants 625 694	Patients with cystic fibrosis receiving intermittent i.v. antibiotics
T4	Participants 1611 1654	patients requiring longer term i.v. access.
